Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims Aquestive made false and misleading statements about the approval timeline for its Anaphylm NDA, failing to disclose significant human factors risks impacting regulatory approval. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave the false impression that its New Drug Application for Anaphylm would be approved by the January 31, 2026 PDUFA date, despite the FDA identifying deficiencies. Investors who suffered losses have until May 4, 2026, to apply to be appointed as lead plaintiff.
The Rosen Law Firm is reminding investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) who purchased securities between June 16, 2025, and January 8, 2026, about the May 4, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Aquestive made false and misleading statements regarding its New Drug Application for Anaphylm, specifically minimizing the significance of human factors in its product's use. Investors who suffered damages are encouraged to contact the firm.
